Brief: Coya Therapeutics Reports Unaudited Second Quarter 2024 Results
12/08/2024 14:03
Aug 12 (Reuters) - Coya Therapeutics Inc COYA.O :
* COYA THERAPEUTICS PROVIDES A CORPORATE UPDATE AND REPORTS
UNAUDITED SECOND QUARTER 2024 FINANCIAL RESULTS
* FDA SAID ADDITIONAL DATA TO BE SUBMITTED BEFORE PHASE 2
STUDY
BIOLOGIC COMBINATION COYA 302 IN PATIENTS WITH ALS
* INTENDS TO DISCUSS RECOMMENDATIONS ON BIOLOGIC COMBINATION
COYA
302 IN PATIENTS WITH ALS WITH FDA IN 4Q 2024
Source text for Eikon: ID:nBw81GjRxa
Further company coverage: COYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)